Technologies that measure activation of components of the DNA damage response (DDR) have applications in exposure assessment and personalized medicine. The DDR and associated DNA repair pathways encompass hundreds of proteins, making detailed measurement of activation technically challenging and laborious. The purpose of our study was to develop proteinspecific assays for certain DDR components on a high-throughput electrochemiluminescence (ECL)-based platform. We developed five working assay pairs for ataxia telangiectasia mutated (ATM), checkpoint kinase 2 (CHK2), phosphorylated-ATM S1981, phosphorylated-CHK2 T68 and phosphorylatedtumor protein p53 (p53) S15. We validated the ECL results against traditional immunoblot and γ-H2AX foci measures in cell and cancer models. In an effort to test the ECL-based technology in a clinical setting, we utilized peripheral blood mononuclear cells (PBMCs) from patients undergoing computed tomography (CT) scans. CT scans represent both a valuable medical imaging diagnostic and a controlled environmental exposure to ionizing radiation for research studies, as they deliver ~2 to 31 millisieverts (mSv) and are known to activate DDR components. In this study, we show that ECL-based technology can measure the basal and damage-induced levels of DDR components in patient PBMC samples. Using a blinded study design and patient matched preand post CT scan samples, we show that ECL-derived data can consistently 
Introduction
Ionizing radiation (IR) promotes the formation of single and double DNA strand breaks by directly damaging the DNA molecule and by generating reactive oxygen species that damage DNA. Both the IR-induced DNA damage and subsequent DNA repair contribute to strand breaks [1] [2] [3] [4] [5] . DNA strand breaks promote the regulation of proteins associated with the DNA damage response (DDR), which includes damage-sensor, damage-transducer and DNA repair systems [6] [7] [8] . Ataxia telangiectasia mutated (ATM) is activated by IR to signal the presence of DNA damage [9] . ATM is a serine/threonine protein kinase which autophosphorylates at serine 1981 (S1981) during the response to DNA strand breaks [10] , provoking its recruitment to double strand breaks to phosphorylate the H2A histone family member, X protein (i.e., γ-H2AX foci) [11] . In response to double strand breaks, ATM will also phosphorylate checkpoint kinase 2 (CHK2) at threonine 68 (T68) to transduce the damage signal and promote downstream phosphorylation of many other proteins [12] . For example, CHK2 can phosphorylate the phosphatase cell division cycle 25 (CDC25) protein to regulate progression through the cell cycle [13] . DNA strand breaks that activate ATM will also promote the phosphorylation of the tumor suppressor protein 53 (p53) at serine 15 (S15) [9] . ATM, CHK2 and p53 signals also regulate cell cycle progression and promote efficient DNA repair. Notably, deficiencies in ATM, CHK2 or p53 lead to genome instability syndromes, cancer predisposition and increased sensitivity to IR exposure [14] - [23] .
While IR can initiate DNA damage, it is also an essential component of medical diagnostic equipment. Computed tomography (CT) scans are radiationbased imaging procedures that have been proven to be valuable clinical tools for the diagnosis of injuries to the lungs, heart, liver, spleen, kidneys and bowel. Side effects of diagnostic CT are exposure-induced DNA damage [24] and increased cancer risk [25] , with the latter potentially influenced by an individual's response to DNA strand breaks. It has been estimated that patients undergoing diagnostic CT receive ~2 millisieverts (mSv) of radiation for a routine head CT, to 31 mSv for abdomen and pelvis CT scans [26] . 31 mSv is a significant amount of radiation, as it has been documented that Hiroshima and Nagasaki atomic bomb survivors who received 10 -100 mSv of radiation had increased cancer risk [27] [28] [29] . The use of diagnostic CT scans in the United States of America has increased from 3 million scans in 1980 to nearly 70 million in 2007, and it has been estimated that diagnostic CT scans will cause approximately 15,000 cancer deaths annually [25] . Furthermore, published reports indicate that diagnostic CT scans promote the formation of γ-H2AX foci in peripheral blood mononuclear cells (PBMCs), supporting the theory that diagnostic imaging using ionizing radiation can in fact provoke a DDR at the cellular level in patients [30] [31] [32] .
A large portion of the U.S. population will be exposed to diagnostic CT scans in their lifetime. The benefits of diagnostic CT scans greatly outweighs the potential adverse effects at this time, but tools that measure an individual's ability to respond to CT scans and repair DNA strand breaks are important due to their potential to identify patients susceptible to CT scan induced disease. The current challenge is that measuring DDR and repair is extremely difficult, and a single all-encompassing assay does not exist. However, a number of individual assays are available to study specific DNA damage levels or components of the DDR.
These assays include the single cell gel electrophoresis assay (COMET) [33] [34] [35], mass spectrometry based quantification of specific DNA lesions [36] , host extract based molecular beacons [37] , microarray analysis of transcripts [38] and fluorescence-based multiplex flow cytometric host cell reactivation assays (FM-HCR) that measure the repair of specific lesions [39] [40] [41] . In general, these assays provide valuable data on the integrity of DNA or parts of the DDR, and each assay has proved to be extremely useful for research studies on the cellular DDR and DNA repair capacity.
The cellular response to DNA damage includes phosphorylation of many sensor, signaling and repair proteins, making post-translational modifications (PTMs) effective biomarkers of DNA damage and indicators of response. High throughput COMET assays, high throughput γ-H2AX foci measures and multiplexed fluorescent host cell reactivation assays have highlighted the value of measuring multiple components or outputs [41] Immunological analysis of epitopes on specific proteins is a proven low-tech approach for analyzing proteins and can be accomplished using immunoblots and enzyme-linked immunosorbent assays (ELISA), and such approaches are the work-horses of most biomedical research and diagnostic labs. Unfortunately, immunoblots and ELISA are not readily applicable to the simultaneous and quantitative analysis of the hundreds of proteins and activated targets associated with the DDR, as they suffer from throughput and dynamic range issues. A developed electrochemiluminescence (ECL) technology platform (from MesoSale Discovery, MSD, Gaithersburg, Maryland) is available for the analysis of many (~3840) proteins/targets from the same sample, representing a technology that could be applied to the problem of measuring individual DDR capacity, since its multi-target approach and enhanced sensitivity overcomes many of the afore-mentioned issues associated with conventional immunoblot/ELISA assays [45] . The system is best described as ECL detection of an antibody captured protein using an electrode-lined microplate to initiate the signal and sensitive optics used to detect the signal. Each well-specific electrode can be coated and linked to a capture antibody, with the capture antibody used to bind a specific sample protein (i.e., the analyte). Once the capture antibody binds the target protein, the well is washed to remove non-specifically bound proteins. Next, a second antibody that is specific to a different epitope on the target protein is added. Importantly, this second antibody is labeled with a sulfo-tag. The ECL reaction is only initiated if the sulfo-tag labeled antibody binds the target protein, as the label will be stimulated to emit light if electricity is passed from the electrode through the bound protein. Importantly, this design helps reduce background signal as the stimulation (electricity) is decoupled from the signal (light) and it provides a wide dynamic range [46] [47] [48] . The drawback of the MSD-ECL technology platform is that it is only as good as the target-specific capture and detection antibodies, which require extensive development and testing.
The main purpose of our study was to identify commercially available antibodies, specific to DDR proteins, which would work effectively in the ECL platform. In addition, we wanted to compare the performance of the ECL platform to standard measures of an activated DDR, and determine if the platform was amenable for use with clinical samples. As such, we have identified 10 commercially available DDR compatible antibodies for use in the above described MSD-ECL technology platform. Using cell culture models and exposure conditions that promote DNA damage (relative to unexposed, base-line, conditions), we have identified antibodies to ATM, CHK2, phosphorylated-ATM S1981, phosphorylated-CHK2 T68 and phosphorylated-p53 S15 that can be used in the MSD-ECL platform to detect activation of the DDR. Importantly, we have validated the clinical utility and suitability of the ECL-based DDR assays using PBMC samples from patients undergoing diagnostic CT scans. We have demonstrated that the ECL-based technology can identify significant protein level changes induced in vivo by diagnostic CT scans.
Material and Methods

Cell Culture and Treatments
The human embryonic kidney cell line HEK-293G was purchased from Invitrogen (Grand Island, NY). The human breast and cancer breast cell lines MCF10A, MCF7, T47D, SW527 and MDA-MB231 were kindly provided by Dr. Ceshi Chen (Albany Medical College, Albany, NY). HEK-293G, MDA-MB231 and SW527 were cultured in Dulbecco's Modified Eagle's Medium (Hyclone, South Logan, UT) supplemented with 10% FBS (Sigma-Aldrich, St. Louis, MO), 100 units/ml penicillin and 100 mg/ml streptomycin (Hyclone) at 37˚C in 5% CO 2 humidified air. MCF10A cells were cultured in F12/DMEM media (Hyclone) with 5% horse serum (Invitrogen), 100 units/ml penicillin and 100 mg/ml streptomycin (Hyclone), 20 ng/ml EGF (Invitrogen), 100 ng/ml cholera toxin (Sigma-Aldrich), 0.01 mg/ml insulin (Invitrogen) and 500 ng/ml hydrocortisone (Sigma-Aldrich) at 37˚C in 5% CO 2 humidified air. MCF7 and T47D cells were cultured in Eagle's MEM (Hyclone) with 10% FBS (Sigma-Aldrich), 100 units/ml penicillin and 100 mg/ml streptomycin (Hyclone) and 0.01 mg/ml insulin (Invitrogen) at 37˚C in 5% CO 2 humidified air. For treatment with chemicals, cells were cultured in medium with bleomycin (Research Products International, Mount Prospect, IL), etoposide (MP Biomedicals, Santa Ana, CA) or H 2 O 2 (ACROS Organics, Geel, Belgium) at concentrations indicated in the figure legends. Ionizing radiation was delivered by a Faxitron X-ray generator (Faxitron, Tucson, AZ). Cells were irradiated and harvested 1 hour after exposure.
Antibodies
All antibodies used for ECL-based detection and immunoblotting are shown in Supplemental Table S1 . The order of addition for ECL-based detection and the concentrations used are also described in Supplemental Table S1.
Cell Staining and Imaging Flow Cytometry
Cells were fixed with 2% paraformaldehyde for 30 minutes on ice followed by permeabilization and staining with an anti-γ-H2AX antibody, directly conju- 
Protein Extraction
Whole cell protein extracts were prepared with lysis buffer (20 mM Tris-Cl, pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100) supplemented with freshly added complete protease inhibitor (Roche Applied Science, Nutley, NJ), phosphatase inhibitor cocktail 2 (Sigma-Aldrich) and phosphatase inhibitor cocktail 3 (Sigma-Aldrich). Protein concentrations were determined using the Bradford protein assay kit (BioRad, Hercules, CA).
Immunoblotting
Whole cell lysates were resolved on SDS-PAGE and then blotted onto PVDF membranes (Millipore). After blocking with 5% nonfat dried milk in TBS-T (20 mM Tris-HCl pH 7.4, 150 mM NaCl, 0.05% Tween-20) for 1 hour, membranes were incubated with specific primary antibodies in TBS-T with 3% BSA (SeraCare Life Sciences, Milford, MA) at 4˚C overnight. After the membrane was washed 4 times with TBS-T, it was incubated for 1 hour at room temperature with the appropriate horseradish peroxidase-conjugated secondary antibody (Pierce/Thermo Fisher, Grand Island, NY) prepared with 3% nonfat milk in TBS-T. The membrane was washed 4 times with TBS-T before protein detection.
Proteins were detected using an ECL western blotting substrate (Pierce/Thermo Fisher) and the Fluorchem M imaging system (Protein Simple, Santa Clara, CA).
ECL-Based Analysis of DDR Targets
96-well plates (MesoScale Discoveries, Rockland, MA) were coated with capture antibodies diluted in PBS at 4˚C overnight. After the plates were washed with the MSD wash buffer (TBS containing 0.2% Tween-20), plates were blocked with a 5% blocker A (BSA) (SeraCare Life Sciences) solution at room temperature for 1 hour. Samples were then added to the wells, incubated at 4˚C overnight or at room temperature for 2 hours. After sample incubation, the plate was washed with wash buffer and the detection antibody (MesoScale Discoveries) was then added to the plates and incubated for 2 hours. Following a further wash with the MSD wash buffer, sulfo-tag anti-species antibodies (MesoScale Discoveries) were then added to each well (0.5 mg/ml) and the plates were incubated for 1 hour at room temperature. Finally, plates were washed with the MSD wash buffer, and MSD read buffer T was added to detect the signal of analyte using the Sector 2400 instrument (MesoScale Discoveries).
Chicken Chorioallantoic Membrane Assay (CAM Assay)
Fertilized White Leghorn chicken eggs (Charles River, Cambridge, MA) were initially incubated for 10 days at 37˚C in a humidified atmosphere inside a hatching incubator equipped with an automatic rotator (Octagon 20, Brinsea, Somerset, UK). Xenografts were then performed as previously described [49] . Briefly, a square window of ~1 cm was opened over the displaced CAM and sealed with a piece of sterile tape. MDA-MB231 cells were detached from the culture plate with 2 mM EDTA in PBS and washed twice in PBS. Cells (2 × 10 6 ) were resuspended in 50 µl PBS containing 1 mM MgCl 2 , 0.5 mM CaCl 2 , 100 U/ml penicillin and 100 µg/ml streptomycin and then inoculated on the CAM. The opening was re-sealed with tape and the eggs were placed in a stationary incubator at 37˚C for 7 days or as indicated. The resulting tumors were removed, photographed and proteins were analyzed as described above.
Blood Draw and PBMC Isolation
After providing informed consent, whole blood samples were collected from subjects prior to, and 1 hour post CTscan for the purpose of clinical diagnosis. Figure   1 (b), phosphorylated ATM S1981, phosphorylated CHK2 T68 and phosphorylated p53 S15 were markedly increased after IR exposure.
Next we focused on the use of DDR markers as initial targets for multiplexed protein quantification assays using MSD's ECL technology platform. As shown in Figure 1 (c), each antibody sandwich assay was initiated by coating with a specific capture antibody that recognizes the targeted protein. After blocking, samples were added, followed by the addition of a detection antibody that recognizes the targeted protein or protein-specific modification. Once the sandwich was formed, an anti-species sulfo-tag antibody was added, which when bound emits light upon electrical stimulation. After screening more than 30 antibodies, we developed five working assays (Figure 1(d) ) that quantitatively measure IR-induced activation of some DDR components in the HEK-293G cells. Capture antibodies included those for phosphorylated ATM S1981, ATM, phosphorylated CHK2 T68, CHK2 and phosphorylated p53 S15. Consistent with immunoblot results, the mean signals of phosphorylated ATM S1981, phosphorylated CHK2 T68, CHK2 and phosphorylated p53 S15 were increased after cells were exposed to IR, while the levels of total ATM protein remain the same. We have performed similar studies using a wide range of culture systems (HEK293G, MCF10A, MCF7, T47D, SW527 and MDA-MB231) exposed to a range of DNA damaging agents (bleomycin, etoposide, H 2 O 2 and 4 Gy IR) to further demonstrate the utility of the assay platform (Supplemental Figure S1 -S3, Table S2) in detecting activation of the DDR. In addition, we have demonstrated that the ECL-based platform can be used to measure IR-induced activation of the DDR in tumor xenografts (Supplemental Figure S4) . We also investigated how much input protein was needed to detect IR-induced activation of the DDR. We determined that the ECL-based assay can detect activation of our DDR components with as little as 1.25 µg of input sample, compared to the 30 µg required for the immunoblotting experiments (Figure 1(e) vs. Figure 1(b) ). Notably, we can detect about a 3-fold increase in phosphorylated p53 S15 signal with 1.25 µg of lysates coming from cells irradiated at 8 Gy. Once protein extracts were produced, the assay was performed in under 3-hours, with the plate based design amenable to high throughput analysis. Ultimately our results support the idea that the developed ECL-based assays are a sensitive, quantitative and fast way to measure the IR-induced activation of DDR components in HEK-293G cells.
We also investigated if the ECL-based approach could detect activation of the DDR after low dose exposure to IR. We decreased the IR dose from 4 to 0.5 -0.05 Gy and determined whether the ECL based methodology could detect activation of the DDR. 1hour after HEK-293G cells were exposed to 0.05 Gy of IR, we detected ~2-fold increases in the levels of phosphorylated ATM S1981 and phosphorylated CHK2 T68, with phosphorylated p53 S15 levels showing little change ( Figure 1(f) ). 1 hour after HEK-293G cells were exposed to 0.1 to 0.5 Gy of IR we could detect further increases in the levels of phosphorylated ATM S1981 (up to ~4-fold) and phosphorylated CHK2 T68 (up to ~5-fold). We observed little change in the levels of phosphorylated p53 S15 when cells were exposed to 0.05 to 0.015 Gy of IR (Figure 1(f) ). Our results using cells in culture demonstrate that the ECL-based assay specific to DDR components can be used with cell lines and laboratory exposures to detect activation of the DDR, even at relatively low IR doses (0.05 Gy). It also begged the question of whether our ECL-based assays could be used to analyze or detect activation of the DDR in humans exposed to low dose ionizing radiation.
Design and Goals of Pilot Clinical Study
Diagnostic CT scans can deliver 2 to 31 mSv of ionizing radiation [26] . Patients undergoing CT scans provide a unique population with a well-controlled exposure to a DNA damaging agent, which is a useful setting for testing our ECLbased assay specific to the DDR. Thus we set up a pilot clinical study (Figure 2) to quantitate DDR protein levels in patient PBMC's before and after a diagnostic CT scan. Specifically, we wanted to determine if (1) the ECL-based assay we developed for some DDR components can identify significant protein level changes induced in vivo by diagnostic CT scan and (2), using blinded samples, can the resulting patient-matched data be used to predict whether samples were pre-or post-CT scan samples. Both results would advise us on the suitably of our assay system for use in larger clinical and population studies.
For this pilot study, we recruited men of any ethnicity between the ages of 18 to 75 with appointments at the Stratton Veterans Administration Hospital (Albany, NY) for a diagnostic CT scan of the chest or abdomen/pelvis, as these procedures use similar amounts of ionizing radiation. Enrolled patients were Figure 2 . Study Design. Participated patients donated 30 ml of whole blood each before and after a diagnostic CT scan. Blood was collected in a sodium heparin glass tube and stored at 4˚C. Blood was transferred from the clinical to research team as blinded patient samples (A or B) that were specific to pre-and post CT scan samples. PBMCs were isolated within 3 hours of post-CT blood draw and stored at −80˚C. Protein was isolated from all supplied samples at the same time and analyzed for the five markers described in Figure 1 . 
Significant Difference in Marker Levels in Patient Matched A and B Samples
We obtained enough protein from each patient's A and B sample to obtain three technical replicates for each analyzed DDR marker, with resulting data reported as the average amount (−/+ standard deviation) of phosphorylated ATM S1981, ATM, phosphorylated CHK2 T68, CHK2 and phosphorylated p53 S15 (Figure 3 ).
The Student's t-test was used to determine if differences were significant (p < 0.05) in the levels of each marker when comparing a patient's A and B samples ( Figure 3 and Table 1 ). Based on past experience and Figure 1 data, ATM levels do not significantly change after exposure to IR, and for the majority of patient- Figure 3 . Intensity of five markers from A and B samples of 16 participated patients.
((a)-(e) Patient specific protein extracts (25 µgs) were analyzed (N = 3) for DDR markers using the Figure 1 described ECL-approach. A and B are the blinded codes for either preor post-CT samples for each patient. Significant differences between each patients A and B sample were determined using the Student's t-test (*p < 0.05, **p < 0.01). S15 levels showed little change in HEK-293G cells exposed to low dose IR (Figure 1(f) ). Similarly, 15 out of the 16 patient matched samples showed no difference in phosphorylated p53 S15 when comparing their A and B samples ( Figure 3 , Table 1 ). In contrast to ATM and phosphorylated p53, we detected significant (p < 0.05) differences in the levels of phosphorylated ATM S1981 (11 out 16 subjects) and CHK2 (12 out of 16 subjects) in a majority of the subjects when comparing their A and B samples ( Figure 3 , Table 1 ). While the differences in CHK2 levels were all less than 2-fold, we did detect up to 3-fold differences in the amount of phosphorylated ATM in some subjects. Lastly we determined significant differences in the levels of phosphorylated CHK2 T68 in 5 of 16 subjects (Figure 3 , Table 1 ), but similar to CHK2 data the observed changes were all less than 2-fold. Also all increases in phosphorylated CHK2 T68 where matched by increases in CHK2 in the same patient.
Metrics Used to Predict Pre-and Post CT-Scan Sample for Each Patient
Data for all five markers were then analyzed in the context of each patient ( Figure 3 , Table 1 ), with the increase in marker levels used to predict the post-ex-posure samples. All 16 patients had a significant change in at least one marker, with 6 patients having recorded significant changes in 3 markers, 3 patients having recorded significant changes in 2 markers and 7 patients having a recorded significant change in only 1 marker. IR-induced DNA double strand breaks will lead to increased activation of ATM, CHK2 and p53. As such, increases in phosphorylated ATM S1981, phosphorylated CHK2 T68 and phosphorylated p53 S15 levels should all be indicators of the post-CT scan sample.
Also based on our assay design, increased CHK2 levels should be an indicator of the post CT scan sample. The 7 patients for which we recorded only one significant increase all had that increase in CHK2 or phosphorylated ATM S1981, which was then used to predict the post-CT sample from A or B (Table 2) . We detected significant (p < 0.05) changes in 2 to 3 markers for 9 patients. For these 9 patients, we detected correlated increases (i.e., the significant increases for each marker were observed in just the A or just the B sample) for 6 patients. This correlated data was then used to predict whether sample A or B was collected pre-or post-CT sample. We observed marker increases in opposite samples for 3
patients. For patient #5 we recorded an increase in ATM and CHK2 in the B sample and increase in phosphorylated ATM S1981 in the A sample. Our validation data reported in Figure 1 supports the idea that total ATM protein levels do not change in response to IR, while phosphorylated ATM S1981 and CHK2 protein levels increase. As the increases were in opposite samples for patient #5's ATM S1981 and CHK2 levels, we viewed the phosphorylated ATM S1981 data as a more reliable predictor because it had a more significant p-value (p < 0.008 vs.
p < 0.043). Thus we used the phosphorylated ATM S1981 data to predict the post-CT sample for patient #5 (Table 2 ). In patient #9 we observed a significant increases in ATM in the A sample and significant increases in CHK2 and phosphorylated CHK2 T68 in the B sample. In patient #9 we used the significant increases in the B sample for phosphorylated CHK2 T68 and CHK2 to predict it as the post-CT scan sample. In patient #14 we detected increases in phosphorylated ATM S1981 and CHK2 in opposite samples. CHK2 had a more significant increase in total signal relative to phosphorylated ATM S1981, p < 0.021 and p < 0.022, respectively, which directed us to use CHK2 as the predictor for the post-CT scan sample.
94% Prediction Accuracy Using ATM S1981, CHK2 and CHK2 T68 Markers
Collectively we used biological and statistical rational to predict the post CT sample for each of the 16 matched patient samples (Table 2 ). When we un-blinded exposure details and aligned them with our quantitative data and compiled predictions, we determined that we had successfully predicted the post CT sample for 15 of the 16 patients (94% accuracy) ( Table 2) . Surprisingly the lone prediction error in our small sample occurred with patient #4 in which we detected correlated increases in CHK2, phosphorylated ATM S1981 and phosphorylated CHK2 T68 in the A sample relative to B, leading to our incorrect designation of A as the post CT scan sample. While 100% is the desired accuracy Table 2 . Pre-and post-CT blood sample predictions and CTscan details. Predictions (columns 2 -6) from individual assays were based on the intensity levels of markers ( Figure 3 ) and p-values listed in Table S4 ). For example, using phosphorylated ATM or phosphorylated CHK2 individually, the prediction accuracy was 50% -56%, but using together with CH2K and phosphorylated p53 the use of four markers increased the accuracy to 94%. Simply put, the use of multiple markers provided the best accuracy and, in many cases, provided redundancy in predicting the post CT scan sample.
One interesting observation specific to phosphorylated ATM S1981 was that three groups of patients with different levels of this marker were observed after CT scan (Figure 4 ). Specifically, we identified groups of patients that had low, medium and high levels of phosphorylated ATM S1981 that were significantly Figure 4 . Stratification of patients based on post CT scan protein levels. The absolute level of phosphorylated ATM from each of 16 patients was ordered from low to high. Groups of patients were compared using the Student's t-test, to identify low, medium and high designates. Student's t-test was used to assess for significant differences in the low, medium and high groups. killing by methylnitronitrosoguanidine (MNNG) [38] . The identified inter-individual differences identified by microarray analysis have application in cancer treatment, as MNNG is representative of some alkylation based chemotherapeutics. Our pilot study also demonstrates inter-individual variability in the response to diagnostic CTs, with patients showing increases in anywhere from one to four marker levels. Notably we have demonstrated that tumors grown from xenografts can be analyzed using our ECL-based assay, which suggests applications in cancer treatment.
Ultimately, the ECL based assay platform we used proved to be highly reliable, providing tight technical replicates for each of the five DDR targets. Our study supports the idea that ECL is a viable technology platform for use with clinical studies. The ECL assay platform has the potential to be expanded to >3450 samples. With over two hundred proteins associated with the DDR and many being post-translationally modified, the ECL technology platform could completely cover the DDR protein space. Increasing the number of DDR proteins that can be analyzed by the ECL-based platform is a future goal.
